Latest News
Research Highlights
International news demonstrating how RWE can improve diagnosis, treatment implementation and patient outcomes.
NOVEMBER 2026
AHA 2026

Real-world cardiovascular outcomes with semaglutide: Insights from a Norwegian SELECT-like population
RWE Research contributed to a nationwide Norwegian registry-based study presented by Prof. Peder L. Myhre (Oslo University Hospital, Norway) at AHA Scientific Sessions 2026.
Among 5,376 SELECT-like patients initiating semaglutide, the observed 12-month incidence of major cardiovascular events was identical to that reported in the SELECT semaglutide arm (MACE-3: 1.7%). All-cause hospitalization rates were also similar (14.0% vs 14.6%).
Exploratory analyses showed lower observed heart failure hospitalization or cardiovascular death rates under stricter treatment-persistence definitions, although these findings require cautious interpretation.
The study provides encouraging real-world evidence of comparable observed outcomes across clinical trial and routine-care populations.
The research was recognized with the Paul Dudley White International Scholar Award, acknowledging scientific excellence in cardiovascular research.

SELECT like RWE results
Paul Dudley White International Scholar Award

OCTOBER 2026
ASN Kidney Week 2026
New insights into CKD progression and cardiorenal outcomes
RWE Research contributed to four scientific presentations at ASN Kidney Week 2026 in Denver, highlighting findings from multinational real-world evidence programmes.
Three complementary analyses from PROMISE and ELEVATE eGFR were presented by Prof. Roberto Pecoits-Filho (Ann Arbor, Michigan, USA), Prof. Tara I. Chang (Stanford University, California, USA), and Prof. Katherine R. Tuttle (Washington, USA).
The studies examined the progression of albuminuria, its association with kidney function decline and cardiorenal risk, and how historical eGFR trajectories are associated with subsequent clinical outcomes.
Together, these findings provide important new insights into identifying patients at increased risk of CKD progression and adverse cardiorenal outcomes.

1.
2.
3.
OCTOBER 2026
ASN Kidney Week 2026
New insights into CKD progression and cardiorenal outcomes
New insights into the clinical and economic burden of CKD and heart failure
RWE Research contributed to the multinational CaRe study presented by Prof. Roberto Pecoits-Filho (University of Michigan, Ann Arbor, USA) at ASN Kidney Week 2026 in Denver.
The study included more than 2.7 million patients across England, Japan, Sweden, and the USA. Patients with coexisting CKD and heart failure consistently experienced higher risks of severe kidney events and CKD-related hospitalizations, alongside substantially greater healthcare costs.
The findings highlight the clinical and economic burden of cardiorenal disease and the importance of preventing CKD progression.

OCTOBER 2026
PATHWAY 2026

AI Meets RWE Research
Unlocking Insights Beyond Conventional Epidemiology
RWE Research AS is proud to join PATHWAY, a NordicRWE-led innovation project awarded NOK 16 million by the Research Council of Norway.
The project aims to unlock clinically meaningful insights from complex healthcare data that are difficult to identify using conventional epidemiological approaches alone.Together with NordicRWE and the University of Oslo, we aim to advance AI-enabled evidence generation for drug development and market access.


JUNE 2026
JACC HF
Cardiorenal Disease PATHWAY and Treatment Inertia
The CaRe Study
A multinational study published in JACC: Heart Failure, analysing more than 760,000 patients from England, Japan, Sweden and the United States. The study demonstrated that chronic kidney disease most commonly precedes heart failure, while guideline-directed medical therapy remained consistently underutilized regardless of disease pathway.
These findings highlight major opportunities for earlier diagnosis, coordinated cardiorenal care and improved implementation of evidence-based therapies.

Stephen J. Greene, Toru Kondo, Johan Bodegard, et al Disease Progression, Cardiorenal Disease Pathways and Treatment of Patients With Comorbid Heart Failure and Chronic Kidney Disease. JACC HF. 2026 June, doi: 10.1016/j.jchf.2026.103179. Epub 2026 June 15.
OCTOBER 2026
BMJ OpenHEART
Our newly published nationwide study examined how heart failure treatments are initiated, sustained and optimised in routine care.
More than 80% of patients starting SGLT2 inhibitors remained on treatment at the target dose during follow-up. Other therapies requiring dose titration showed substantially lower target-dose attainment, and treatment persistence was consistently lower following outpatient than inpatient initiation.
During 2022–2023, SGLT2 inhibitor use reached approximately 45–55% among patients with newly diagnosed heart failure, compared with only 10–12% among those with established disease.
These findings highlight opportunities to strengthen treatment review and long-term follow-up in chronic heart failure. They also provide a benchmark for assessing progress as treatment adoption continues to evolve.
Heart failure GDMT implementation across two countries
The CaRe Study
Norhammar A, Sveen KA, Bodegård J, et al. Implementation gaps in contemporary heart failure therapy: a two-country nationwide analysis. Open Heart. 2026;13.

JUNE 2026
ERA 2026
Oral presentation: MRA initiation, hyperkalaemia risk and treatment persistence across kidney function groups
The CaRe Study


Presented by Prof. Roberto Pecoits-Filho (Pontifical Catholic University of Paraná, Brazil), this analysis evaluated real-world use of mineralocorticoid receptor antagonists (MRAs) in patients with comorbid heart failure and chronic kidney disease across different levels of kidney function. MRA initiation was associated with only modest average increases in serum potassium, yet hyperkalaemia risk remained high, particularly among patients with impaired kidney function. More than half of patients discontinued treatment within two years, highlighting persistent barriers to durable MRA therapy in routine cardiorenal care. These findings underscore the importance of optimized potassium management strategies to support appropriate and sustained MRA use in high-risk patients.

Presented by prof Roberto Pecoits-Filho, USA at
The 63rd European Renal Association Congress
Glasgow, United Kingdom, June 2026.
JUNE 2026
ERA 2026
Oral presentation: Proteinuria testing patterns in primary care patients with chronic kidney disease: results from England and the USA
The PROMISE Study
Presented by Prof. James Burton (University of Leicester). The PROMISE study demonstrated that proteinuria testing remains markedly underutilized in primary care CKD management, particularly among patients without T2D, potentially limiting timely identification of high-risk patients eligible for guideline-directed cardiorenal-protective therapies.

Presented by prof James O. Burton, UK at
The 63rd European Renal Association Congress
Glasgow, United Kingdom, June 2026.
MAY 2026
ECO 2026
Nationwide analysis of obesity pharmacotherapy reveals individualized real-world use of semaglutide 2.4 mg
This nationwide analysis evaluated obesity medication use in more than 140,000 individuals in Norway. The study demonstrated a rapid increase in predominantly self-funded semaglutide 2.4 mg use, which has reshaped the Norwegian obesity treatment landscape. Real-world utilization was characterized by highly individualized dose titration patterns, frequent treatment interruptions and patient-driven dose adjustments ("click-counting"), highlighting important differences between clinical trial protocols and routine clinical practice.
These findings demonstrate the value of real-world evidence for understanding the implementation and long-term use of innovative obesity therapies.


Presented Jens K Hertel, Norway, at
The 33rd European Congress on Obesity
Istanbul, Türkiye, May 2026
MAY 2026
ESC HF 2026
Rapid fire presentation: Initiation of MRA in HF and CKD - potassium trajectories, hyperkalaemia and treatment persistence
The CaRe Study
New findings presented by Prof. Stephen Greene (Duke University School of Medicine, Durham, North Carolina, USA) from the CaRe Study demonstrate early and dose-dependent increases in serum potassium following MRA initiation in patients with heart failure and chronic kidney disease. Hyperkalaemia risk increased over time, while treatment persistence declined substantially, with more than half of patients discontinuing treatment within two years. These findings highlight important barriers to sustained MRA use in routine clinical practice and underscore the need for treatment strategies that are both effective and well tolerated in this high-risk population.


Presented prof Stephen Greene at
ESC Heart Failure 2026,
Barcelona, Spain, May 2026
NOVEMBER 2025
ASN
Cardiorenal disease and severe renal outcomes
The CaRe Study
RWE findings presented by Prof. Roberto Pecoits-Filho (Pontifical Catholic University of Paraná, Brazil) from Japan, Sweden and the USA demonstrated that patients with combined chronic kidney disease (CKD) and heart failure face a substantially worse kidney prognosis than those with either condition alone. These findings highlight the considerable burden of cardiorenal disease and underscore the urgent need for improved treatment strategies in this high-risk population.
Presented by prof Roberto Pecoits-Filho, USA at
ASN Kidney Week 2025
Houston, Texas, USA, November 2025.
SEPTEMBER 2025
Adv Ther
UACR 700 mg/g: CKD progression, cardiorenal risk and SGLT2i effects
The OPTIMISE-CKD Study


RWE from the USA shows that patients with CKD and high-risk proteinuria (UACR ≥ 700 mg/g) experience rapid kidney function decline and markedly higher risks of hospitalization and death. Although SGLT2i provide expected benefits, substantial residual albuminuria highlights the urgent need for improved treatment strategies in this high-risk population.
Pecoits-Filho R, Bodegård J, et al. Disease Progression, Clinical Outcomes and Treatment Challenges in Patients with Chronic Kidney Disease and High-Risk Proteinuria. Adv Ther. 2025 Nov;42(11):5653-5668. doi: 10.1007/s12325-025-03364-8. Epub 2025 Sep 15. PMID: 40952621; PMCID: PMC12579703.
AUGUST 2025
ESC 2025
Cardiorenal disease and risks of hospitalizations for HF and CKD
The CaRe Study
RWE findings presented by Prof. Stephen Greene (Duke University School of Medicine, USA) from Japan, Sweden and the USA demonstrated that patients with combined heart failure (HF) and chronic kidney disease (CKD) face substantially higher risks of all-cause mortality and HF- and CKD-related hospitalizations than patients with either condition alone. These findings highlight the severe prognosis associated with cardiorenal disease and underscore the need for integrated management and optimized guideline-directed medical therapy (GDMT) in this high-risk population.
Presented prof Gianluigi Savarese, Sweden at
ESC Congress 2025
Madrid, Spain, August 2025.
AUGUST 2025
ESC 2025
Incident cardiorenal disease and changes in GDMT for HF
The CaRe Study
RWE findings presented by Prof. Gianluigi Savarese (Karolinska Institutet and Södersjukhuset, Stockholm, Sweden) from Japan, Sweden and the USA demonstrated that patients with incident heart failure (HF) and chronic kidney disease (CKD) receive consistently low levels of guideline-directed medical therapy (GDMT), both before and after diagnosis. Despite modest treatment increases following incident HF+CKD, substantial implementation gaps persisted, highlighting the need for earlier identification and optimized management of this high-risk cardiorenal population.
Presented prof Gianluigi Savarese, Sweden at
ESC Congress 2025
Madrid, Spain, August 2025.
JULY 2025
BMC Nephrology
CKD with and without T2D: Risks and GDMT utilization
The OPTIMISE-CKD study
Nationwide RWE from Norway shows that diagnosed CKD is associated with high risks of hospitalization, mortality, and substantial healthcare costs, irrespective of diabetes status. Despite increasing uptake of SGLT2 inhibitors, overall use of kidney-protective therapies remains low—highlighting an urgent need for better GDMT implementation and risk management in CKD.
Jenssen TG, Bodegård J. et al Prevalence, outcomes, costs, and treatments of a contemporary population with chronic kidney disease in Norway: a nationwide observational study. BMC Nephrol. 2025 Jul 17;26(1):393. doi: 10.1186/s12882-025-04171-7. PMID: 40676552; PMCID: PMC12273365.
2 JULY 2025
NICE
Low UACR Restriction for SGLT2i
The OPTIMISE-CKD Study
NICE reversed its prior restriction on dapagliflozin for CKD patients with low UACR (non-T2D, low albuminuria) based on new real-world evidence. This decision reflects growing confidence in high-quality RWE to fill evidence gaps where RCT data are limited.

Svensson MK, Tangri N, Bodegård J, et al Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD). Clin Kidney J. 2024 Apr 4;17(8):sfae100. doi: 10.1093/ckj/sfae100. PMID: 39165293; PMCID: PMC11333959.
MAY 2025
NDT
CKD stage 3-4: UACR, Risks and Guideline-directed Medical Treatment Utilization
The OPTIMISE-CKD Study
RWE from Finland shows that stage 3–4 CKD is highly prevalent, with most patients being non-T2D yet experiencing similarly high risks of hospitalization and death. Albuminuria testing and use of kidney-protective therapies were low—especially in non-T2D patients—highlighting an urgent need for improved CKD detection and preventive treatment.
Metsärinne K, Bodegård J, et al. Characteristics, treatment and disease burden among stage 3-4 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016-2022. Nephrol Dial Transplant. 2025 May 30;40(6):1115-1123. doi: 10.1093/ndt/gfae242. PMID: 39510970; PMCID: PMC12209851.
17 MAY 2025
ESC HF 2025
Cardiorenal Disease Pathways
The CaRe Study
RWE findings presented by Prof. Stephen Greene (Duke University School of Medicine, USA) demonstrated distinct pathways leading to combined heart failure (HF) and chronic kidney disease (CKD), including HF→CKD, CKD→HF and simultaneous presentation of both conditions. Across all pathways, substantial gaps in guideline-directed medical therapy (GDMT) utilization and limited nephrology involvement were observed. These findings highlight opportunities for earlier detection, improved multidisciplinary management and more integrated cardiorenal care.
Presented prof Stephen Greene at
ESC Heart Failure 2025
Belgrade, Serbia, May 2025.
12 FEBRUARY 2025
EHJ
Suspected de novo heart failure The REVOLUTION HF Study
This RWE study showed that patients presenting in outpatient care with suspected de novo HF—defined by new HF signs or symptoms and elevated NT-proBNP—face an immediate and very high risk of HF hospitalization and death. Risks were highest in the first weeks after presentation, underscoring the need for rapid identification, evaluation, and initiation of HF therapy.
Anderson L, Bayes-Genis A, Bodegård J, Mullin K, Gustafsson S, Rosano GMC, Sundström J. Suspected de novo heart failure in outpatient care: the REVOLUTION HF study. Eur Heart J. 2025 Apr 22;46(16):1493-1503. doi: 10.1093/eurheartj/ehaf034. PMID: 39935142; PMCID: PMC12011520.







